This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BNC375 Alzheimer's Disease Drug Candidate Presented At Neuroscience Conference

  • BNC375 enhances episodic and working memory
  • Performance matches Donepezil (US$2.5 billion sales in 2011) in animal tests

ADELAIDE, South Australia, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) today announced that new data on BNC375, its drug candidate with potential for the treatment of memory loss in Alzheimers Disease, will be presented at the 33rd Annual Meeting of the Australian Neuroscience Society taking place in Melbourne from 3 – 6 February 2013 at the Melbourne Convention Centre.

BNC375, which is a positive allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), will be the focus of Poster #143 which will be exhibited today Monday, 4 February 2013 from 12.30pm -2.30pm.

The poster highlights data demonstrating the in vivo memory enhancing properties of this drug candidate in two animal models of cognitive impairment as well as data on the action of BNC375 on the receptor. The animal model data indicates that BNC375 enhances both episodic memory and working memory and that it has equivalent performance compared to Donepezil, a Pfizer product marketed as Aricept with reported US$2.5 billion sales in 2011. BNC375 has a 100-fold therapeutic dose range, from 0.1 to 10 mg/kg and has demonstrated a wide therapeutic window in the preclinical studies conducted to date.

"BNC375 targets Alzheimer's disease and other conditions which are associated with significant memory loss," said Dr Deborah Rathjen, Bionomics' CEO and Managing Director.

"This latest drug candidate to come from our technology platform conforms to Bionomics' focus on developing well differentiated drug candidates to treat serious conditions such as Alzheimer's disease, Schizophrenia and Parkinson's disease amongst others," she added.

There is a large body of evidence implicating the α7 nAChR in the pathophysiology of several neurodegenerative and neuropsychiatric diseases. Modulation of this receptor enhances cognitive processes, for example working memory and attention, which are compromised in these disorders.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs